The Biden administration formally moved to withdraw the rule on Executive Order 139337, which requires certain 340B grantees to offer reduced-price insulin and injectable epinephrine to low-income patients. During the initial rulemaking, NCPA provided comments to HHS and HRSA highlighting concerns about administrative fees for these prescriptions and the potential additional regulatory burdens placed on pharmacists. The Biden administration feels that the current rule would “harm the program and the patients it serves as a whole.” However, for now the Executive Order remains in effect. NCPA will continue to work with HHS to ensure patient access and affordability for these important drugs.
NCPA
